Attached files
file | filename |
---|---|
EX-31.2 - EX-31.2 - PROVECTUS BIOPHARMACEUTICALS, INC. | d145017dex312.htm |
EX-31.1 - EX-31.1 - PROVECTUS BIOPHARMACEUTICALS, INC. | d145017dex311.htm |
10-Q - FORM 10-Q - PROVECTUS BIOPHARMACEUTICALS, INC. | d145017d10q.htm |
Exhibit 32
CERTIFICATION PURSUANT TO RULE 13a-14(b) UNDER
THE SECURITIES EXCHANGE ACT OF 1934 AND
SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE
Each of the undersigned, Peter R. Culpepper, the Interim Chief Executive Officer and Chief Operating Officer of Provectus Biopharmaceuticals, Inc. (the Company), and John R. Glass, the Interim Chief Financial Officer of the Company, certifies, pursuant to Rule 13a-14(b) under the Securities and Exchange Act of 1934 (the Exchange Act) and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act, and (2) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This Certification is signed on May 10, 2016.
By: |
/s/ Peter R. Culpepper | |
Peter R. Culpepper Interim Chief Executive Officer Chief Operating Officer |
By: |
/s/ John R. Glass | |
John R. Glass Interim Chief Financial Officer |